NAPSRx News: New global fund established for dementia research

WASHINGTON - March 17, 2015 - PRLog -- The Dementia Discovery Fund has been established by the UK government to fuel research and development for Dementia which pose a serious threat to public health and healthcare systems globally according to the World Health Organization. Key investors include pharmaceutical giants such as GlaxoSmithKline investing $25 million and Johnson and Johnson (J& J) putting up $10 million to jumpstart this initiative. Biogen Idec, Eli Lilly and Pfizer will also make contributions toward this fund.

The ultimate goal of this research fund is to identify novel therapeutics that may effectively  treat  Alzheimer's and other forms of dementia.  The financial support and scientific expertise in the early stages of research the development will accelerate the progress of new treatments for this disease. The scientific advisory board will include representatives from the partner organizations who will provide accompanying advice during the selection of research programmes, pre-clinical and early clinical development.

Patrick Vallance, President of Pharmaceutical R&D at GSK, said: “The rise of dementia is fast becoming one of the world’s greatest health threats, and in order to reverse the tide on this, it’s imperative that the scientific community works together, sharing knowledge and expertise with one another. Today’s announcement signals a unique opportunity for us to translate some of the world’s most promising research in this field in to life changing medicines. This Fund is a really smart way of bringing together great minds and communally increasing our understanding of dementia. It’s also a good way of sharing the financial risk associated with conducting drug discovery research in this field."

44 million people worldwide suffer from dementia and according to the World Health Organization that number will triple by 2050.

Candidates who want to break into pharmaceutical sales:

Now is the time to enter this wonderful career field! With such industry leaders paving the way on identifying new beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to promote their product both proficiently and efficiently.

The NAPSRx® is a trade association for pharmaceutical sales reps, sales managers and sales trainers who work in the pharmaceutical industry. NAPSRx® provides Continuing Medical Education to its members as well as CNPR® Certification to candidates who look to enter a pharmaceutical sales career. The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/.